

This notice in TED website: <http://ted.europa.eu/udl?uri=TED:NOTICE:408158-2016:TEXT:EN:HTML>

**United Kingdom-Runcorn: Pharmaceutical products
2016/S 224-408158**

Contract award notice

Results of the procurement procedure

Supplies

Directive 2014/24/EU

Section I: Contracting authority

I.1) Name and addresses

The Secretary of State for Health acting as part of the Crown through the Commercial Medicines Unit
2nd Floor, Rutland House
Runcorn
WA7 2ES
United Kingdom
E-mail: sarah.blackman@dh.gsi.gov.uk
NUTS code: UK

Internet address(es):

Main address: <https://cmu.bravosolution.co.uk>
Address of the buyer profile: <https://cmu.bravosolution.co.uk>

I.2) Joint procurement

The contract is awarded by a central purchasing body

I.4) Type of the contracting authority

Ministry or any other national or federal authority, including their regional or local subdivisions

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title:

NHS Pharmaceuticals 2016_2.
Reference number: CM/PHG/12/5379

II.1.2) Main CPV code

33600000

II.1.3) Type of contract

Supplies

II.1.4) Short description:

Invitation to offer for NHS Pharmaceuticals 2016_2.
CM/PHG/12/5379.
Period of framework agreement: Dates detailed below with options to extend up to a maximum period of 36 months.

Potential periods of call-offs under the framework agreement:

North West and Eastern and North London: 1.1.2017 to 31.1.2018 (13 months).

South East and South London and North East and Yorkshire: 1.1.2017 to 30.6.2018 (18 months).

Central and South West: 1.1.2017 to 30.6.2017 (6 months).

II.1.6) **Information about lots**

This contract is divided into lots: yes

II.1.7) **Total value of the procurement (excluding VAT)**

Value excluding VAT: 68 800 000.00 GBP

II.2) **Description**

II.2.1) **Title:**

NHS Pharmaceuticals 2016_2

Lot No: Central and South West: 1.1.2017 to 30.6.2017 (6 months)

II.2.2) **Additional CPV code(s)**

33600000

II.2.3) **Place of performance**

NUTS code: UK

Main site or place of performance:

Please see below.

II.2.4) **Description of the procurement:**

NHS Pharmaceuticals 2016_2.

CM/PHG/12/5378.

Period of framework agreement: Dates detailed below with options to extend up to a maximum period of 36 months.

Potential periods of call-offs under the framework agreement:

Central and South West: 1.1.2017 to 30.6.2017 (6 months).

The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England. The framework may also be used by private sector contractors and agents working on behalf of the above. Please refer to Document 10 in the Invitation To Offer Documents for the list of Purchasing Points.

II.2.5) **Award criteria**

Quality criterion - Name: The most economically advantageous tender in terms of the criteria stated in the specifications, in the invitation to tender or to negotiate or in the descriptive document / Weighting: See over

Cost criterion - Name: The most economically advantageous tender in terms of the criteria stated in the specifications, in the invitation to tender or to negotiate or in the descriptive document / Weighting: See over

II.2.11) **Information about options**

Options: yes

Description of options:

Dates detailed below with options to extend for up to another 6 months.

Central and South West: 1.1.2017 to 30.6.2017 (6 months).

II.2.13) **Information about European Union funds**

The procurement is related to a project and/or programme financed by European Union funds: no

II.2.14) **Additional information**

II.2) **Description**

II.2.1) **Title:**

NHS Pharmaceuticals 2016_2

Lot No: South East, South London, North East and Yorkshire: 1.1.2017 to 30.6.2018 (18 months)

II.2.2) **Additional CPV code(s)**

33600000

II.2.3) **Place of performance**

NUTS code: UK

Main site or place of performance:

Please see below.

II.2.4) **Description of the procurement:**

NHS Pharmaceuticals 2016_1 Offer reference number: CM/PHG/12/5378 Period of framework agreement: Dates detailed below with options to extend up to a maximum period of 36 months Potential periods of call-offs under the framework agreement:

South East, South London, North East and Yorkshire — 1.1.2017 to 30.6.2018 (18 months).

The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England. The framework may also be used by private sector contractors and agents working on behalf of the above. Please refer to Document 10 in the Invitation To Offer Documents for the list of Purchasing Points.

II.2.5) **Award criteria**

Quality criterion - Name: The most economically advantageous tender in terms of the criteria stated in the specifications, in the invitation to tender or to negotiate or in the descriptive document / Weighting: See over

Cost criterion - Name: The most economically advantageous tender in terms of the criteria stated in the specifications, in the invitation to tender or to negotiate or in the descriptive document / Weighting: See over

II.2.11) **Information about options**

Options: yes

Description of options:

Dates detailed below with options to extend for up to another 18 months.

South East and South London and North East and Yorkshire: 1.1.2017 to 30.6.2018 (18 months).

II.2.13) **Information about European Union funds**

The procurement is related to a project and/or programme financed by European Union funds: no

II.2.14) **Additional information**

II.2) **Description**

II.2.1) **Title:**

NHS Pharmaceuticals 2016_2

Lot No: North London and North West: 1.1.2017 to 31.1.2018 (13 months)

II.2.2) **Additional CPV code(s)**

33600000

II.2.3) **Place of performance**

NUTS code: UK

Main site or place of performance:

Please see below.

II.2.4) **Description of the procurement:**

Invitation to offer for NHS Pharmaceuticals 2016_2.

CM/PHG/12/5379.

Period of framework agreement: Dates detailed below with options to extend up to a maximum period of 36 months.

Potential periods of call-offs under the framework agreement:

North West and Eastern and North London: 1.1.2017 to 31.1.2018 (13 months).

The framework agreement is intended for use by the Department of Health, Public Health England and the NHS in England. The framework may also be used by private sector contractors and agents working on behalf of the above. Please refer to Document 10 in the Invitation To Offer Documents for the list of Purchasing Points.

II.2.5) **Award criteria**

Quality criterion - Name: He most economically advantageous tender in terms of the criteria stated in the specifications, in the invitation to tender or to negotiate or in the descriptive document / Weighting: See over

Cost criterion - Name: He most economically advantageous tender in terms of the criteria stated in the specifications, in the invitation to tender or to negotiate or in the descriptive document / Weighting: See over

II.2.11) **Information about options**

Options: yes

Description of options:

Dates detailed below with options to extend for up to another 13 months:

North West and Eastern and North London: 1.1.2017 to 31.1.2018 (13 months).

II.2.13) **Information about European Union funds**

The procurement is related to a project and/or programme financed by European Union funds: no

II.2.14) **Additional information**

Section IV: Procedure

IV.1) **Description**

IV.1.1) **Type of procedure**

Open procedure

IV.1.3) **Information about a framework agreement or a dynamic purchasing system**

The procurement involves the establishment of a framework agreement

IV.1.6) **Information about electronic auction**

IV.1.8) **Information about the Government Procurement Agreement (GPA)**

The procurement is covered by the Government Procurement Agreement: yes

IV.2) **Administrative information**

IV.2.1) **Previous publication concerning this procedure**

Notice number in the OJ S: [2016/S 088-155078](#)

IV.2.8) **Information about termination of dynamic purchasing system**

IV.2.9) **Information about termination of call for competition in the form of a prior information notice**

Section V: Award of contract

Contract No: CM/PHG/12/5379

Lot No: 1

Title:

NHS Pharmaceuticals 2016_2

A contract/lot is awarded: yes

V.2) **Award of contract**

V.2.1) **Date of conclusion of the contract:**

10/11/2016

V.2.2) **Information about tenders**

Number of tenders received: 16

Number of tenders received by electronic means: 16

The contract has been awarded to a group of economic operators: no

V.2.3) **Name and address of the contractor**

Please see Section VI.3)

This Section refers to all Lots within this tender

Please see Section VI.3)

United Kingdom

NUTS code: UK

The contractor is an SME: yes

V.2.4) **Information on value of the contract/lot (excluding VAT)**

Total value of the contract/lot: 34 400 000.00 GBP

V.2.5) **Information about subcontracting**

Section VI: Complementary information

VI.3) **Additional information:**

Awarded Suppliers:

Brancaster Pharma Ltd;

Drugsrus Limited;

Flynn Pharma Ltd;

Fresenius Kabi Limited;

GlaxoSmithKline UK Ltd;

Intrapharm Laboratories Ltd;

Novartis Pharmaceuticals UK Ltd;

Reig Jofre Group;

Sandoz Ltd;

Torrent Pharma (UK) Ltd;

Wockhardt UK Limited.

A List of purchasing points can be provided upon request.

VI.4) **Procedures for review**

VI.4.1) **Review body**

The Secretary of State for Health acting as part of the Crown through the Commercial Medicines Unit (part of the Department of Health)

Runcorn

United Kingdom

VI.4.2) **Body responsible for mediation procedures**

VI.4.3) **Review procedure**

VI.4.4) **Service from which information about the review procedure may be obtained**

VI.5) **Date of dispatch of this notice:**

17/11/2016